公开(公告)号：US20160339032A1

公开(公告)日：2016-11-24

申请号：US15233520

申请日：2016-08-10

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Roch Boivin ,  Eric Carlson ,  Atsushi Endo ,  Hans Hansen ,  Lynn D. Hawkins ,  Sally Ishizaka ,  Matthew Mackey ,  Sridhar Narayan ,  Takashi Satoh ,  Shawn Schiller

IPC: A61K31/519 ,  A61K31/55

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/55 ,  C07D487/04 ,  Y02P20/582

Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis

公开(公告)号：US09446046B2

公开(公告)日：2016-09-20

申请号：US14806174

申请日：2015-07-22

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Roch Boivin ,  Eric Carlson ,  Atsushi Endo ,  Hans Hansen ,  Lynn D. Hawkins ,  Sally Ishizaka ,  Matthew Mackey ,  Sridhar Narayan ,  Takashi Satoh ,  Shawn Schiller

IPC: A01N43/90 ,  A61K31/519 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/55 ,  C07D487/04 ,  Y02P20/582

Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

公开(公告)号：US09000024B2

公开(公告)日：2015-04-07

申请号：US14173170

申请日：2014-02-05

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark Spyvee ,  Takashi Satoh ,  Jonathan Eric Carlson

IPC: C07D231/22 ,  C07D231/20

CPC classification number: C07D231/22 ,  C07D231/20

Abstract: The present invention provides compounds of Formula I: along with pharmaceutical compositions containing the same, and methods of use thereof in subjects in need of treatment.

Abstract translation: 本发明提供式I化合物以及含有其的药物组合物及其在需要治疗的受试者中的使用方法。

公开(公告)号：US08686018B2

公开(公告)日：2014-04-01

申请号：US13795768

申请日：2013-03-12

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Mark Spyvee ,  Takashi Satoh ,  Jonathan Eric Carlson

IPC: A61K31/415 ,  C07D231/20 ,  A61P29/00

CPC classification number: C07D231/22 ,  C07D231/20

Abstract: The present invention provides compounds of Formula I: along with pharmaceutical compositions containing the same, and methods of use thereof in subjects in need of treatment.

Abstract translation: 本发明提供式I化合物以及含有其的药物组合物及其在需要治疗的受试者中的使用方法。

公开(公告)号：US10537571B2

公开(公告)日：2020-01-21

申请号：US15627851

申请日：2017-06-20

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Dominic Reynolds ,  Ming-Hong Hao ,  John Wang ,  Sudeep Prajapati ,  Takashi Satoh ,  Anand Selvaraj

IPC: A61K31/505 ,  A61K31/506 ,  A61K31/5377

Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.